Telix to Present 20 Abstracts at EANM 2026 Congress

Telix has announced that it will be presenting 20 company-related abstracts at the forthcoming 39th Annual Congress of the European Association of Nuclear Medicine (EANM) scheduled for October 17-21, 2026, in Vienna, Austria.

Dr. David N. Cade, Chief Medical Officer of Telix, emphasized that the company's robust presence at the event showcases the extensive development of its pipeline, which includes important therapeutic studies, precision diagnostics, and advanced technologies. He noted that the inclusion of 12 abstracts in top-rated oral presentations is a significant acknowledgment of the quality and clinical relevance of Telix's research. A symposium focusing on the future of theranostics in urologic oncology is also planned.

Key presentations will feature pivotal trials such as the Phase 3 IPAX BrIGHT trial of TLX101-Tx in recurrent glioblastoma, the Phase 3 LUTEON trial of TLX250-Tx in clear cell renal cell carcinoma (ccRCC), and interim results from the PTherpan-Lu trial of TLX597-Tx in metastatic androgen pathway modulation-resistant prostate cancer (mAPMR). The event will also highlight topline Phase 3 data for TLX591-Px (Illuccix) PET imaging in prostate cancer among Chinese men, as well as real-world applications of TLX250-Px (Zircaix) in ccRCC.

Additionally, Telix will sponsor the EANM Sanjiv Sam Gambhir Young Investigator Award to honor the legacy of the esteemed educator.

Attendees can visit booth #527 to learn more about collaboration opportunities involving Illuccix®, the PSMA-PET imaging agent, along with contributions from Telix's theranostic pipeline and innovative medical technologies, including the SENSEI® miniature drop-in gamma probe and QDOSE® dosimetry software.

Sponsored Symposium Details

Title: The future doesn’t wait: The next era of theranostics in urologic oncology.
Date & Time: 18-Oct-26, 13:15 – 14:45
Location: Hall F2, Austria Center Vienna
Chair: J. Calais, Gustave Roussy, IGR and Université Paris-Saclay, Paris, France

Agenda:

• The theranostic revolution
• The evolving role of PSMA-PET in prostate cancer
• Next-generation PSMA therapeutics: Overcoming today’s challenges
• Panel discussion
• Extending prostate cancer theranostic success to broader GU diseases

Selected Oral Presentations

1. ELEGANCE: Prospective pilot study assessing imaging performance of TLX250-Px in patients with hepatocellular carcinoma, biliary tract cancer or gastro-enteropancreatic neuroendocrine neoplasms.
2. • Date and Time: 18-Oct-26, 08:00 – 09:30
   • Presenter: Clement Bailly
2. HIMIKO: TLX591-Px PET/CT in hepatocellular carcinoma.
3. • Date and Time: 18-Oct-26, 08:00 – 09:30
   • Presenter: Rachel Bardy
3. Exploring carbonic anhydrase IX as a diagnostic imaging target using TLX250-Px in Von Hippel-Lindau Disease.
4. • Date and Time: 18-Oct-26, 15:00 – 16:30
   • Presenter: Fabrizia Gelardi
4. LUTEON: Phase 3 study assessing safety and efficacy of TLX250-Tx in advanced ccRCC.
5. • Date and Time: 18-Oct-26, 15:00 – 16:30
   • Presenter: Ghoufrane Tlili
5. Building the traceability backbone for radiopharmaceutical therapy: First results from the PDIB Secondary Standards Laboratory Network.
6. • Date and Time: 19-Oct-26, 08:00 – 09:30
   • Presenter: Steven Graves

With the exception of Illuccix, all products mentioned are investigational and have not received marketing authorization in any jurisdiction.